Janux Therapeutics
Engineers antibodies that stay dormant until reaching a tumor, then engage T cells.
$18.10
After-hours close+0.09 (+0.50%)
At close$18.01(−4.10%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 101.48%Insiders 1.65%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 60.98M · Float 57.09M · 93.6% free float
Institutions13F, as of Jun 30, 2026
205 holders · 61.89M shares · 40 new positions · 121 increased · 47 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 11.19M | 18.35% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.13M | 10.06% | +701.4K | Aug 7, 2026 |
| Prosight Management, LP | 3.80M | 6.24% | +254.5K | Aug 14, 2026 |
| State Street Corp | 3.00M | 4.93% | +540.9K | Aug 7, 2026 |
| FMR LLC | 2.41M | 3.96% | −122.9K | Aug 13, 2026 |
| Federated Hermes, Inc. | 2.35M | 3.86% | +2.30M | Aug 12, 2026 |
| Point72 Asset Management, L.P. | 1.99M | 3.27% | +837.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.86M | 3.05% | +46.0K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 19.90% | 11.97M | 13D | Mar 10, 2025 ↗ |
| Janus Henderson Group PLC | 6.90% | 4.20M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.70% | 3.35M | 13G | Jul 17, 2025 ↗ |
| Prosight Management, LP | 5.20% | 3.15M | 13G | Feb 6, 2026 ↗ |
| Point72 Asset Management, L.P. | 5.00% | 3.07M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| David Alan Campbell | director, officer: President and CEO | 264.7K | 0.43% | Jul 31, 2026 |
| Thomas DiRaimondo | officer: Chief Scientific Officer | 124.4K | 0.20% | Jan 2, 2026 |
| Sheila Gujrathi | director | 118.9K | 0.19% | Jun 13, 2025 |
| Andrew Hollman Meyer | officer: Chief Business Officer | 83.1K | 0.14% | Jan 2, 2026 |
| Vickie L. Capps | director | 79.6K | 0.13% | Jun 12, 2026 |
| Charles M. Winter | officer: Chief Technical Officer | 77.7K | 0.13% | Jan 2, 2026 |
| Janeen Noel Doyle | officer: Chief Corp. & Bus. Dev. Ofcr | 75.9K | 0.12% | Jun 4, 2026 |
| William Go | officer: Chief Medical Officer | 44.0K | 0.07% | Feb 4, 2026 |
| Maria Dobek | officer: Vice President, Accounting | 32.3K | 0.05% | May 13, 2026 |
| Zachariah McIver | officer: Chief Medical Officer | 23.3K | 0.04% | Jan 2, 2026 |
3 ten-percent owners hold 3.62M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (1.22M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 2, 2026 | Janeen Noel Doyleofficer: Chief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $14.03 | 75,941 |
| May 11, 2026 | Maria Dobekofficer: Vice President, Accounting | Sale | 2,038 | $14.17 | 32,270 |
| Jan 2, 2026 | Maria Dobekofficer: Vice President, Accounting | Sale | 1,462 | $13.73 | 15,373 |
| Jan 2, 2026 | Zachariah McIverofficer: Chief Medical Officer | Sale | 2,714 | $13.73 | 23,286 |
| Jan 2, 2026 | Charles M. Winterofficer: Chief Technical Officer | Sale | 2,401 | $13.73 | 77,721 |
| Jan 2, 2026 | David Alan Campbelldirector, officer: President and CEO | Sale | 8,072 | $13.73 | 284,982 |
| Jan 2, 2026 | Thomas DiRaimondoofficer: Chief Scientific Officer | Sale | 2,505 | $13.73 | 124,425 |
| Jan 2, 2026 | Andrew Hollman Meyerofficer: Chief Business Officer | Sale | 1,879 | $13.73 | 83,095 |
| Dec 1, 2025 | Andrew Hollman Meyerofficer: Chief Business Officer | Sale · 2 lots | 3,333 | $32.98 | 84,974 |
| Nov 14, 2025 | Andrew Hollman Meyerofficer: Chief Business Officer | Sale | 3,333 | $30.00 | 84,974 |
CongressHouse and Senate disclosures
Not reported.